Therapeutic apheresis treatment in rheumatic diseases: Insights from a single-center experience

• Published in: Therapeutic apheresis and dialysis
• Main Authors: Çimen Güneş, Ezgi, Tekgöz, Emre, Çolak, Seda, Sayın, Selim, Şirin, Hülya, Aylı, Meltem, Çınar, Muhammet, Yılmaz, Sedat
• Format: Journal Article
• Language: English
• Published: Australia 26.08.2024
• Subjects: therapeutic plasma exchange; systemic lupus erythematosus; catastrophic antiphospholipid antibody syndrome; vasculitis
• ISSN: 1744-9987; 1744-9987
• DOI: 10.1111/1744-9987.14199

We aimed to evaluate the characteristics of the patients with a rheumatologic disease who underwent TPE. A single-center, retrospective study was conducted between January 2016 and June 2023. Twenty patients with a median age of 51 years received a median of 6 TPE sessions. Concurrently, immunosuppressive therapy was administered to 18 (90%) of them. During the follow-up period, 9 patients (45%) died. Creatinine (p = 0.001), C-reactive protein (p = 0.001), sedimentation rate (p = 0.002), leukocyte (p = 0.003), thrombocyte (p = 0.003), and neutrophil (p = 0.003) counts was decreased after TPE. Similarly, in the ROC analysis of post TPE laboratory parameters, urea, creatinine, CRP, hemoglobin, platelets, and lymphocytes predicted mortality with areas under the curve values ranging from 0.747 to 0.869. In the Cox regression analysis for mortality, creatinine was predictive for mortality (p = 0.030), HR 1.59 (95% CI: 1.05-2.41). In rheumatologic conditions, TPE is beneficial to fill the gap until the effects of immunosuppressants become apparent.